Literature DB >> 19322549

[Precancerous and early invasive carcinomas: non-surgical treatment of head and facial skin].

E Haneke1.   

Abstract

Chronic exposure to sunlight with its high proportion of high energy ultraviolet light is the main cause of the common cutaneous precancerous lesions and carcinomas of the head and neck. This causes a field cancerization effect frequently with multiple actinic keratoses (AKs), basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs). Although demonstrating the best cure rates and lowest recurrence rates, surgical excision rapidly progresses to its limits. Field cancerization requires field therapy. Non-specific caustic agents may remove superficial lesions, however, the modern therapeutic modalities such as topical cytotoxic treatment with 5-fluorouracil, photodynamic therapy with 5-aminolevulinic acid (ALA) or its methyl ester (MeALA), the topical immune response modifier imiquimod or the local application of the cyclooxygenase inhibitor diclofenac are more specific and effective. Intralesional and perilesional injections of cytotoxic agents and interferons as well as the new targeted anti-cancer drugs are further alternatives. The most important aspect, however, is the prophylaxis of chronic photodamage.

Entities:  

Mesh:

Year:  2009        PMID: 19322549     DOI: 10.1007/s00106-009-1892-5

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  74 in total

1.  Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream.

Authors:  M Shane Chapman; Steven K Spencer; Jeoffry B Brennick
Journal:  Arch Dermatol       Date:  2003-07

2.  Extensive lentigo maligna clearing with topical imiquimod.

Authors:  Ernst Epstein
Journal:  Arch Dermatol       Date:  2003-07

3.  Hundreds of basal cell carcinomas in a Gorlin-Goltz syndrome patient cured with imiquimod 5% cream.

Authors:  J R Ferreres; A Macaya; A Jucglà; C Muniesa; C Prats; J Peyrí
Journal:  J Eur Acad Dermatol Venereol       Date:  2006-08       Impact factor: 6.166

4.  A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses.

Authors:  H A Kurwa; S A Yong-Gee; P T Seed; A C Markey; R J Barlow
Journal:  J Am Acad Dermatol       Date:  1999-09       Impact factor: 11.527

5.  Treatment of eyelid epithelial neoplasm by targeting sonic hedgehog signaling: an experimental study.

Authors:  Ken-Ichi Miyazaki; Shizuya Saika; Osamu Yamanaka; Yuka Okada; Yoshitaka Ohnishi
Journal:  Jpn J Ophthalmol       Date:  2006 Jul-Aug       Impact factor: 2.447

6.  Successful treatment of earlobe keloids with imiquimod after tangential shave excision.

Authors:  Mitchell E Stashower
Journal:  Dermatol Surg       Date:  2006-03       Impact factor: 3.398

7.  Topical 1% cidofovir for the treatment of basal cell carcinoma.

Authors:  Donato Calista
Journal:  Eur J Dermatol       Date:  2002 Nov-Dec       Impact factor: 3.328

8.  Invasive squamous cell carcinoma after treatment of carcinoma in situ with 5% imiquimod cream.

Authors:  Michelle S Y Goh
Journal:  Australas J Dermatol       Date:  2006-08       Impact factor: 2.875

9.  Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery.

Authors:  Lindy L Thomsen; Peter Topley; Maria G Daly; Sara J Brett; John P Tite
Journal:  Vaccine       Date:  2004-04-16       Impact factor: 3.641

10.  Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer.

Authors:  Donatella Paolino; Donato Cosco; Rita Muzzalupo; Elena Trapasso; Nevio Picci; Massimo Fresta
Journal:  Int J Pharm       Date:  2007-11-28       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.